Merck & Co Inc.

2026-09-21 23:06; UTC

Merck's KEYTRUDA QLEX™ injection has been approved for subcutaneous use in Japan, with the stock remaining roughly flat in after-market trading.

2026-09-18 23:06; UTC

Merck & Co Inc declined in after-market trading, moving from a small gain to a modest loss and remaining below its 20-day moving average.

2026-09-17 20:07; UTC

Merck's shares are advancing following positive Phase 3 trial results for its collaboration with Moderna on a personalized mRNA cancer therapy for melanoma.

2026-09-16 23:51; UTC

Merck & Co Inc is advancing in after-market trading, supported by positive U.S. retail sales data, despite ongoing concerns over TIC flows and Treasury yields.

2026-09-15 23:01; UTC

Merck & Co Inc shares are lower in after-market hours. Broader market sentiment is impacted by a significant decline in the New York Empire State Manufacturing Index.

2026-09-14 23:06; UTC

Merck & Co Inc shares rose in after-market trading following Monday's close, despite earlier declines and no specific news to explain the movement.

2026-09-11 19:36; UTC

Merck & Co Inc shares are declining amid broader market trends following inflation data that heightened interest rate hike speculation. No specific company news was identified.

2026-09-10 20:07; UTC

Merck & Co Inc shares are lower today despite HSBC raising its price target to $172 and noting insider buying activity.

2026-09-09 19:36; UTC

Merck & Co. shares are lower after a court upheld Medicare's drug-price negotiations, raising concerns about future prescription drug spending.

2026-09-08 23:06; UTC

Merck & Co. shares are higher after Karim Mikhail's appointment to lead the FDA's Center for Biologics Evaluation and Research, boosting the company's regulatory reputation.

2026-09-04 23:05; UTC

Merck & Co Inc shares are higher in after-market trading, despite no specific news. Broader market signals show mixed economic indicators and rising Treasury yields.

2026-09-03 23:05; UTC

Merck & Co Inc shares are lower in after-market hours, reflecting a slight decline since Thursday's close amid broader market gains.

2026-09-02 19:46; UTC

Merck & Co Inc is rising following positive results from the ATLAS-UC Phase 3 trial, which met its primary endpoint of clinical significance.

2026-09-01 23:07; UTC

Merck & Co Inc. shares were roughly flat during after-market hours, with no specific company news identified amid broader market fluctuations driven by rising oil prices.

2026-08-31 23:16; UTC

Merck & Co Inc shares are trading higher in after-market hours. Broader market sentiment is influenced by escalating geopolitical tensions and inflation concerns.

2026-08-28 23:01; UTC

Merck & Co Inc shares are higher in after-market trading, supported by rising Treasury yields and trading above their 20-day moving average.

2026-08-27 23:01; UTC

Merck & Co Inc. shares are higher in after-market trading, reflecting routine performance despite three consecutive lower sessions. The stock remains above its 20-day moving average.

2026-08-26 23:11; UTC

Merck & Co Inc is higher in after-market hours, reflecting broader market gains. The stock remains above its 20-day moving average.

2026-08-25 23:06; UTC

Merck & Co Inc reached all-time highs in after-market trading, gaining over $6 amid positive social media sentiment and broader market dynamics.

2026-08-24 23:16; UTC

Merck & Co Inc shares are higher in after-market trading, showing stable performance since Monday's close. The stock remains above its 20-day moving average.

2026-08-21 19:31; UTC

Merck & Co Inc shares are higher today as Goldman Sachs and Morgan Stanley upgraded their ratings and raised price targets, citing confidence in cancer treatments.

2026-08-20 19:31; UTC

Merck & Co Inc shares are lower today following downgrades from RBC Capital and UBS, with both firms setting a price target of $150.

2026-08-19 23:41; UTC

Merck & Co Inc shares declined in after-market trading despite positive Phase 3 trial results for its mRNA-based therapy combined with KEYTRUDA.

2026-08-17 19:36; UTC

Merck & Co Inc shares are higher during Monday's session, reflecting a slight cumulative return since Friday's close amid rising long-term Treasury yields.

2026-08-15 00:01; UTC

Merck & Co Inc shares are lower in after-market hours following notable volatility during the session, despite mixed global market performance.

2026-08-14 23:21; UTC

Merck & Co Inc shares are lower in after-market trading following a decline in U.S. retail sales for July, raising concerns about consumer demand.

2026-08-13 23:06; UTC

Merck & Co Inc. shares were roughly flat in after-market hours, remaining above their 20-day moving average after three consecutive sessions of higher finishes.

2026-08-12 19:56; UTC

Daiwa Capital upgraded Merck to Outperform, raising the price target to $143. The stock remains higher since Tuesday's close amid positive FDA news.

2026-08-11 19:36; UTC

Merck & Co. shares are lower today despite Argus Research maintaining a Buy rating and raising the price target to $145.

2026-08-10 19:36; UTC

Merck & Co Inc disclosed a $3.76 million stake in Evaxion Biotech, boosting shares higher amid positive sentiment and strong options trading ahead of earnings.